Opaque rebate retention collapses the moment regulators force transparent net-cost pricing.
To preempt antitrust action and state-level bans on vertical integration, pharmacy benefit managers are strategically abandoning spread pricing and offshore rebate pools in favor of flat-fee administrative models.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Optum Rx transitioned to a flat-fee model to proactively guard against incoming federal and state-level bans on spread pricing and rebate retention.
Cigna must abandon lucrative offshore rebate capture and transition its Evernorth division to flat administrative fees in the wake of the FTC's antitrust consent order.
This shift transitions the PBM's business model to transparent flat fees to bypass regulatory bans on spread pricing and rebate-retention.
CVS is voluntarily switching to transparent pricing structures to proactively defend its Caremark business against impending federal spread-pricing bans.
The health service arm of UnitedHealth is preemptively abandoning rebate retention for a flat-fee model to manage regulatory risk.